Atyr Pharma Inc., of San Diego, said it entered a $20 million credit facility with Silicon Valley Bank and Solar Capital Ltd. and intends to use the additional capital to pay off existing indebtedness and for general corporate purposes to develop therapies based on its understanding of physiocrine biology.